| Literature DB >> 24725405 |
Susann Weissmueller1, Eusebio Manchado2, Michael Saborowski2, John P Morris2, Elvin Wagenblast3, Carrie A Davis3, Sung-Hwan Moon4, Neil T Pfister4, Darjus F Tschaharganeh2, Thomas Kitzing2, Daniela Aust5, Elke K Markert6, Jianmin Wu7, Sean M Grimmond8, Christian Pilarsky5, Carol Prives4, Andrew V Biankin9, Scott W Lowe10.
Abstract
Missense mutations in the p53 tumor suppressor inactivate its antiproliferative properties but can also promote metastasis through a gain-of-function activity. We show that sustained expression of mutant p53 is required to maintain the prometastatic phenotype of a murine model of pancreatic cancer, a highly metastatic disease that frequently displays p53 mutations. Transcriptional profiling and functional screening identified the platelet-derived growth factor receptor b (PDGFRb) as both necessary and sufficient to mediate these effects. Mutant p53 induced PDGFRb through a cell-autonomous mechanism involving inhibition of a p73/NF-Y complex that represses PDGFRb expression in p53-deficient, noninvasive cells. Blocking PDGFRb signaling by RNA interference or by small molecule inhibitors prevented pancreatic cancer cell invasion in vitro and metastasis formation in vivo. Finally, high PDGFRb expression correlates with poor disease-free survival in pancreatic, colon, and ovarian cancer patients, implicating PDGFRb as a prognostic marker and possible target for attenuating metastasis in p53 mutant tumors.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24725405 PMCID: PMC4001090 DOI: 10.1016/j.cell.2014.01.066
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582